TipRanks on MSN

Eli Lilly’s retatrutide study: A new hope for CKD treatment?

Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...
Healio

Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

2 predictions for Eli Lilly in 2026

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...
StockStory.org on MSN

Why Eli Lilly (LLY) stock is trading up today

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the ...
Fierce Biotech

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

Eli Lilly just delivered fantastic news to investors

Eli Lilly’s weight loss drugs have delivered blockbuster sales in recent quarters. The company is a leader in this market ...